Siltuximab is under clinical development by Recordati and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Siltuximab’s likelihood of approval (LoA) and phase transition for Amyloidosis took place on 22 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 22 Apr 2022 increased Siltuximab’s LoA and PTSR for Metastatic Adenocarcinoma of The Pancreas, and increased LoA and PTSR for Pancreatic Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Siltuximab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Siltuximab overview

Siltuximab (Sylvant), is an anti-IL-6 chimeric monoclonal antibody. It is formulated as lyophilized powder for solution for intravenous administration. It is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human Herpesvirus-8 (HHV-8) negative metastatic pancreatic adenocarcinoma and pancreatic cancer. 

Siltuximab (Sylvant, CNTO-328) is under development for the treatment of  coronavirus disease (COVID-19). It is also under development for the treatment multiple myeloma and AL amyloidosis. It was also under development for the treatment of metastatic renal cell carcinoma, B-cell non-Hodgkin lymphoma, metastatic hormone refractory prostate cancer, myelodysplastic syndrome, refractory and relapsed multiple myeloma and smoldering multiple myeloma (SMM).

Recordati overview

Recordati, a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.

Quick View Siltuximab LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Siltuximab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
Key Developers
  • Sponsor Company: Recordati
  • Originator: Centocor
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.